6 June 2024 in Journal of Dermatological Treatment
Purpose: This study aimed to evaluate the efficacy of tranexamic acid (TXA) in treating melasma through a meta-analysis and systematic review of randomized controlled trials (RCTs). The study focused on identifying associated adverse effects and comparing TXA's effectiveness with other melasma treatments.Materials and methods: Following PROSPERO and PRISMA guidelines, an extensive electronic search was conducted across four databases for RCTs on TXA use in melasma. Inclusion criteria encompassed full-text English articles with specific outcome measures, while studies with high bias risk or non-English publications were excluded. Data were extracted from 22 relevant studies and analyzed using the RevMan software, with heterogeneity identified using I² statistics and forest plots.Results: A total of 22 studies with 1280 patients were included. TXA was administered orally, topically, or via injection, with treatment durations ranging from 8 weeks to nearly 2 years. TXA significantly reduced melasma severity, evidenced by reductions in MASI, mMASI, MI, and hemi-MASI scores. Oral TXA showed the most substantial decrease in MASI scores, followed by injections and topical applications. However, studies exhibited high heterogeneity, particularly in combined treatments. Adverse effects included gastrointestinal discomfort, skin irritation, and menstrual irregularities.Conclusions: TXA is effective in treating melasma, either alone or combined with other treatments. Despite significant reductions in melasma severity, further research is necessary to standardize TXA administration methods and address long-term effects. The high heterogeneity observed suggests a need for more consistent treatment protocols.
8 March 2021 in International Journal of Dermatology
15 May 2025 in Dermatology Reports
Glomus tumors are rare, benign neoplasms arising from glomus bodies, primarily located in the subungual region and upper extremities, but uncommonly reported in areas such as the scrotum. Here, we describe a unique case of a glomus tumor of the scrotal skin in a 28-year-old male presenting with a two-year history of a painful, gradually enlarging scrotal nodule. Clinical examination revealed a tender oblong nodule, and dermoscopy suggested a benign neoplasm. Imaging and initial biopsy confirmed the lesion as a possible glomus tumor. Remarkably, during biopsy, the tumor spontaneously and completely “popped out”, narrowing the differential diagnosis to glomus tumor, angiolipoma, and epidermoid cyst. Histopathology confirmed the diagnosis of a glomus tumor, showing classic features including thick-walled blood vessels surrounded by smooth muscle actin-positive cells and a pseudocapsule. Postoperative pain resolution supported the clinical diagnosis. This case highlights the importance of considering glomus tumors in the differential diagnosis of painful scrotal lesions, especially when a mass exhibits spontaneous ejection during manipulation. To our knowledge, this is the first reported case of a scrotal glomus tumor in Saudi Arabia.